Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Axovant Gene Therapies

DB:3ASA
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3ASA
DB
$98M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Axovant Gene Therapies has significant price volatility in the past 3 months.
3ASA Share Price and Events
7 Day Returns
11.7%
DB:3ASA
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-71.3%
DB:3ASA
-13.5%
DE Biotechs
-20.9%
DE Market
3ASA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Axovant Gene Therapies (3ASA) 11.7% -14.2% -48.7% -71.3% -97.9% -
DE Biotechs -0.7% -7.8% -21.1% -13.5% 12.9% -11.9%
DE Market -0.6% -16.6% -26% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 3ASA underperformed the Biotechs industry which returned -13.5% over the past year.
  • 3ASA underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
3ASA
Industry
5yr Volatility vs Market

Value

 Is Axovant Gene Therapies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Axovant Gene Therapies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Axovant Gene Therapies.

DB:3ASA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:3ASA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 19%) (16.81%))
1.234
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.23
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.234 * 6.07%)
7.1%

Discounted Cash Flow Calculation for DB:3ASA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Axovant Gene Therapies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:3ASA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.1%)
2020 -68.00 Analyst x1 -63.49
2021 -90.05 Analyst x2 -78.50
2022 -111.70 Analyst x2 -90.92
2023 -73.00 Analyst x2 -55.48
2024 70.50 Analyst x2 50.03
2025 121.05 Analyst x2 80.20
2026 162.08 Est @ 33.89% 100.26
2027 200.34 Est @ 23.61% 115.72
2028 233.22 Est @ 16.41% 125.77
2029 259.73 Est @ 11.37% 130.78
Present value of next 10 years cash flows $314.00
DB:3ASA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $259.73 × (1 + -0.39%) ÷ (7.1% – -0.39%)
$3,453.32
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,453.32 ÷ (1 + 7.1%)10
$1,738.86
DB:3ASA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $314.00 + $1,738.86
$2,052.86
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,052.86 / 39.50
$51.97
DB:3ASA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:3ASA represents 0.92369x of NasdaqGS:AXGT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.92369x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 51.97 x 0.92369
€48.00
Value per share (EUR) From above. €48.00
Current discount Discount to share price of €2.30
= -1 x (€2.30 - €48.00) / €48.00
95.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Axovant Gene Therapies is available for.
Intrinsic value
>50%
Share price is €2.3 vs Future cash flow value of €48
Current Discount Checks
For Axovant Gene Therapies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Axovant Gene Therapies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Axovant Gene Therapies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Axovant Gene Therapies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Axovant Gene Therapies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3ASA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.95
NasdaqGS:AXGT Share Price ** NasdaqGS (2020-04-03) in USD $2.49
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Axovant Gene Therapies.

DB:3ASA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AXGT Share Price ÷ EPS (both in USD)

= 2.49 ÷ -2.95

-0.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Axovant Gene Therapies is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Axovant Gene Therapies is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Axovant Gene Therapies's expected growth come at a high price?
Raw Data
DB:3ASA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
61.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Axovant Gene Therapies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Axovant Gene Therapies's assets?
Raw Data
DB:3ASA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.22
NasdaqGS:AXGT Share Price * NasdaqGS (2020-04-03) in USD $2.49
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:3ASA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AXGT Share Price ÷ Book Value per Share (both in USD)

= 2.49 ÷ 0.22

11.24x

* Primary Listing of Axovant Gene Therapies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Axovant Gene Therapies is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Axovant Gene Therapies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Axovant Gene Therapies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Axovant Gene Therapies expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Axovant Gene Therapies expected to grow at an attractive rate?
  • Axovant Gene Therapies's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Axovant Gene Therapies's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Axovant Gene Therapies's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:3ASA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3ASA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 61.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3ASA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3ASA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2025-03-31 850 50 435 4
2024-03-31 509 -44 243 4
2023-03-31 139 -73 -3 4
2022-03-31 0 -65 -100 6
2021-03-31 0 -56 -84 8
2020-04-06
2020-03-31 0 -67 -73 8
DB:3ASA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -61 -65
2019-09-30 -82 -85
2019-06-30 -91 -105
2019-03-31 -134 -129
2018-12-31 -157 -145
2018-09-30 -170 -169
2018-06-30 -204 -204
2018-03-31 -190 -222
2017-12-31 -198 -249
2017-09-30 -180 -239
2017-06-30 -141 -212
2017-03-31 -112 -181

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Axovant Gene Therapies's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Axovant Gene Therapies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3ASA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Axovant Gene Therapies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3ASA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2025-03-31 14.84 39.55 1.71 3.00
2024-03-31 7.92 20.82 -0.10 3.00
2023-03-31 0.36 2.91 -1.56 3.00
2022-03-31 -2.42 -1.99 -2.87 5.00
2021-03-31 -2.30 -1.48 -2.79 7.00
2020-04-06
2020-03-31 -2.89 -1.85 -3.18 7.00
DB:3ASA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.95
2019-09-30 -4.19
2019-06-30 -5.71
2019-03-31 -8.02
2018-12-31 -9.99
2018-09-30 -12.17
2018-06-30 -15.16
2018-03-31 -16.51
2017-12-31 -18.94
2017-09-30 -18.55
2017-06-30 -16.81
2017-03-31 -14.60

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Axovant Gene Therapies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Axovant Gene Therapies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Axovant Gene Therapies has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Axovant Gene Therapies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Axovant Gene Therapies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Axovant Gene Therapies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Axovant Gene Therapies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Axovant Gene Therapies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Axovant Gene Therapies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Axovant Gene Therapies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3ASA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -65.03 23.09 43.34
2019-09-30 -85.28 28.61 56.56
2019-06-30 -105.23 34.18 71.22
2019-03-31 -129.07 39.47 87.55
2018-12-31 -145.34 35.55 102.20
2018-09-30 -168.94 42.65 118.07
2018-06-30 -204.20 62.14 135.12
2018-03-31 -221.57 71.91 141.41
2017-12-31 -249.09 81.96 160.41
2017-09-30 -239.00 75.27 159.70
2017-06-30 -212.16 54.61 153.21
2017-03-31 -180.95 45.72 134.78
2016-12-31 -157.79 40.58 117.42
2016-09-30 -173.33 57.46 115.11
2016-06-30 -146.25 53.76 92.43
2016-03-31 -133.15 56.52 76.64
2015-03-31 -50.51 16.13 34.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Axovant Gene Therapies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Axovant Gene Therapies has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Axovant Gene Therapies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Axovant Gene Therapies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Axovant Gene Therapies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Axovant Gene Therapies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Axovant Gene Therapies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Axovant Gene Therapies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Axovant Gene Therapies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Axovant Gene Therapies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Axovant Gene Therapies Company Filings, last reported 3 months ago.

DB:3ASA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 5.05 15.30 27.81
2019-09-30 17.04 34.36 60.26
2019-06-30 29.35 39.39 84.18
2019-03-31 56.21 44.18 107.00
2018-12-31 22.76 48.83 84.94
2018-09-30 19.88 53.32 90.73
2018-06-30 25.83 53.04 92.93
2018-03-31 71.29 52.68 154.34
2017-12-31 106.65 52.39 188.25
2017-09-30 153.18 52.07 235.37
2017-06-30 206.20 51.75 297.86
2017-03-31 124.84 51.44 212.57
2016-12-31 166.46 0.00 200.41
2016-09-30 205.94 0.00 229.66
2016-06-30 240.25 0.00 252.66
2016-03-31 266.74 0.00 276.25
2015-03-31 -7.75 0.00
  • Axovant Gene Therapies's level of debt (303.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if Axovant Gene Therapies's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Axovant Gene Therapies has less than a year of cash runway based on current free cash flow.
  • Axovant Gene Therapies has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.6% each year.
X
Financial health checks
We assess Axovant Gene Therapies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Axovant Gene Therapies has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Axovant Gene Therapies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Axovant Gene Therapies dividends.
If you bought €2,000 of Axovant Gene Therapies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Axovant Gene Therapies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Axovant Gene Therapies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3ASA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 315 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3ASA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2025-03-31
2024-03-31
2023-03-31
2022-03-31
2021-03-31
2020-04-06
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Axovant Gene Therapies has not reported any payouts.
  • Unable to verify if Axovant Gene Therapies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Axovant Gene Therapies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Axovant Gene Therapies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Axovant Gene Therapies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Axovant Gene Therapies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Axovant Gene Therapies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Axovant Gene Therapies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pavan Cheruvu
COMPENSATION $1,028,744
AGE 37
TENURE AS CEO 2.2 years
CEO Bio

Dr. Pavan Cheruvu, M.D., has been Chief Executive Officer of Axovant Sciences Ltd. since February 12, 2018 and as its Director since September 26, 2018. Dr. Cheruvu provides medical oversight for Hale’s work in cardiovascular health. He serves as an General Cardiology fellow at UCSF’s Cardiac Catheterization Laboratory. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant and supporting Axovant since 2015 and was appointed to the Roivant executive leadership team in 2017. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company from June 2008 through June 2011, where he focused on biopharmaceutical strategy. He earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry from Duke University summa cum laude, his M.Sc. in computer science from Oxford University where he was a Rhodes Scholar, and his M.D. from Harvard Medical School. Prior to joining Axovant, Dr. Cheruvu worked at RSI since October 2015, and was appointed to RSI’s executive leadership team in September 2017.

CEO Compensation
  • Pavan's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Pavan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Axovant Gene Therapies management team in years:

2.2
Average Tenure
53
Average Age
  • The tenure for the Axovant Gene Therapies management team is about average.
Management Team

Pavan Cheruvu

TITLE
CEO & Director
COMPENSATION
$1M
AGE
37
TENURE
2.2 yrs

Gavin Corcoran

TITLE
Chief R&D Officer of Axovant Sciences
COMPENSATION
$1M
AGE
56
TENURE
1.8 yrs

David Nassif

TITLE
CFO, Principal Accounting Officer & General Counsel
AGE
65
TENURE
0.8 yrs

Fraser Wright

TITLE
Chief Technology Officer
TENURE
2.3 yrs

Tricia Truehart

TITLE
Head of Investor Relations

Marianne Dinsmore

TITLE
Head of Global Transactions & Risk Management
COMPENSATION
$1M
AGE
51
TENURE
5.1 yrs

Ilise Lombardo

TITLE
Chief Medical Officer
TENURE
5 yrs

Shankar Ramaswamy

TITLE
Chief Business Officer
TENURE
2.2 yrs

Parag Meswani

TITLE
Senior VP of Commercial Strategy & Operations
TENURE
1.4 yrs

Paul Korner

TITLE
Senior VP of Clinical Development
AGE
53
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Axovant Gene Therapies board of directors in years:

1.6
Average Tenure
40.5
Average Age
  • The average tenure for the Axovant Gene Therapies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Frank Torti

TITLE
Chairperson
COMPENSATION
$282K
AGE
40
TENURE
1.6 yrs

Pavan Cheruvu

TITLE
CEO & Director
COMPENSATION
$1M
AGE
37
TENURE
1.6 yrs

Berndt A. Modig

TITLE
Independent Director
COMPENSATION
$63K
AGE
60
TENURE
5.1 yrs

Atul Pande

TITLE
Lead Independent Director
COMPENSATION
$72K
AGE
64
TENURE
1.6 yrs

Michael Hayden

TITLE
Senior Scientific Advisor & Chairman of the Scientific Advisory Board
AGE
68
TENURE
1.9 yrs

Ilan Oren

TITLE
Director
AGE
35
TENURE
1.8 yrs

Senthil Sundaram

TITLE
Director
AGE
41
TENURE
0.8 yrs

Eric Venker

TITLE
Director
AGE
32
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Axovant Gene Therapies individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 20 Buy Atul Pande Individual 16. Mar 20 16. Mar 20 10,000 €1.60 €15,990
27. Feb 20 Buy Roivant Sciences Ltd. Company 24. Feb 20 24. Feb 20 5,333,333 €3.45 €18,425,999
17. Jun 19 Buy Pavan Cheruvu Individual 14. Jun 19 14. Jun 19 7,500 €4.64 €34,820
17. Jun 19 Buy Atul Pande Individual 14. Jun 19 14. Jun 19 3,370 €4.65 €15,679
X
Management checks
We assess Axovant Gene Therapies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Axovant Gene Therapies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, and Parkinson’s diseases. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Gene Therapies Ltd. is a subsidiary of Roivant Sciences Ltd.

Details
Name: Axovant Gene Therapies Ltd.
3ASA
Exchange: DB
Founded: 2014
$91,170,001
39,502,059
Website: http://www.axovant.com
Address: Axovant Gene Therapies Ltd.
11-12 St. James's Square,
3rd Floor,
London,
Greater London, SW1Y 4LB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AXGT Common Shares Nasdaq Global Select US USD 12. Jun 2015
DB 3ASA Common Shares Deutsche Boerse AG DE EUR 12. Jun 2015
MUN 3ASA Common Shares Boerse Muenchen DE EUR 12. Jun 2015
Number of employees
Current staff
Staff numbers
57
Axovant Gene Therapies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 04:51
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/02
Last earnings filing: 2020/02/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.